KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Current Assets (2016 - 2025)

West Pharmaceutical Services' Current Assets history spans 17 years, with the latest figure at $1.8 billion for Q3 2025.

  • For Q3 2025, Current Assets rose 17.59% year-over-year to $1.8 billion; the TTM value through Sep 2025 reached $1.8 billion, up 17.59%, while the annual FY2024 figure was $1.5 billion, 20.57% down from the prior year.
  • Current Assets for Q3 2025 was $1.8 billion at West Pharmaceutical Services, up from $1.7 billion in the prior quarter.
  • Across five years, Current Assets topped out at $2.0 billion in Q3 2023 and bottomed at $1.3 billion in Q1 2021.
  • The 5-year median for Current Assets is $1.7 billion (2024), against an average of $1.7 billion.
  • The largest annual shift saw Current Assets skyrocketed 35.75% in 2021 before it dropped 21.38% in 2024.
  • A 5-year view of Current Assets shows it stood at $1.7 billion in 2021, then grew by 10.19% to $1.9 billion in 2022, then increased by 0.88% to $1.9 billion in 2023, then fell by 20.57% to $1.5 billion in 2024, then rose by 18.54% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for WST's Current Assets are $1.8 billion (Q3 2025), $1.7 billion (Q2 2025), and $1.5 billion (Q1 2025).